



## **NEUWAY Pharma and Cobra Biologics collaborate to develop GMP grade Engineered Protein Capsules (EPCs) manufacturing process**

*Collaboration supports GLP toxicity studies and initiation of clinical development for treatment of Progressive Multifocal Leukoencephalopathy*

**Keele, UK and Bonn, Germany, 11 October 2016:** Cobra Biologics Ltd, an international CDMO of biologics and pharmaceuticals, and NEUWAY Pharma GmbH, a biopharmaceutical company developing drugs for the treatment of severe orphan CNS diseases, announce today the conclusion of a Service Agreement to develop a manufacturing process for the production of GMP grade material of Engineered Protein Capsules (EPCs) using SF9 cells and subsequent baculovirus infection. The material will be used by NEUWAY for the conduct of GLP toxicity studies and initiation of clinical development in the treatment of Progressive Multifocal Leukoencephalopathy, a very severe neurodegenerative CNS disease. NEUWAY Pharma also uses its EPCs as a CNS Drug Delivery Platform by filling them with active drug substances.

Dr Heiko Manninga, Chief Scientific Officer (CSO) and Managing Director of NEUWAY Pharma commented: “The initiation of GMP development is an important step towards qualification of EPCs for clinical development. We are very happy that we have gained Cobra Biologics as partner for the GMP manufacturing of Engineered Protein Capsules.”

Peter Coleman, CEO Cobra Biologics commented: “We are very pleased to be manufacturing NEUWAY Pharma’s EPCs for what is a rare but serious disease, often resulting in severe disability or death. With Cobra’s 17 years of virus production experience we hope this is just the beginning of our collaboration.”

For more information visit on Neuway Pharma visit [www.neuway-pharma.com](http://www.neuway-pharma.com) and for Cobra Biologics, [www.cobrabio.com](http://www.cobrabio.com)

**ENDS**

**Notes to Editors:**

---

## **Contacts**

### **Media enquiries**

Sarah Jeffery

Zyme Communications

E-mail: [sarah.jeffery@zymecommunications.com](mailto:sarah.jeffery@zymecommunications.com)

Phone: +44 (0)7771 730919

### **At Cobra Biologics**

Peter Coleman

Chief Executive Officer

E-mail: [peter.coleman@cobrabio.com](mailto:peter.coleman@cobrabio.com)

Phone: +44 (0)1782 714181

### **At NEUWAY Pharma GmbH**

Christine Kuhn

E-mail: [kuhn@neuway-pharma.com](mailto:kuhn@neuway-pharma.com)

Phone: +49-(0)228-522798-15

### **About Cobra Biologics ([www.cobrabio.com](http://www.cobrabio.com))**

Cobra Biologics is a leading international contract manufacturing organisation (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract services, stretching from cell line and process development through to fill and finish for the supply of products for clinical trials and the commercial market.

We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra supplies manufacturing solutions to the pharmaceutical industry covering antibodies, recombinant proteins, viruses, phage, DNA, microbiota vaccines and therapeutics as well as biologics and small molecule API lyophilisation and fill finish.

### **About NEUWAY Pharma ([www.neuway-pharma.com](http://www.neuway-pharma.com))**

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of severe orphan brain diseases based on its proprietary CNS Drug Delivery Platform. The company also intends to partner its drug delivery technology for application to proprietary compounds of pharmaceutical companies to exploit their therapeutic use in the field of CNS indications. In addition, NEUWAY initiated the development of a vaccine to treat a rare but frequently fatal neurological disease called progressive multifocal leukoencephalopathy (PML). NEUWAY was founded in April 2014 as the first spin-off from Life Science Inkubator GmbH, Bonn, Germany, where it was nurtured for 4 years and supported with approximately € 2.3 million in research funding by the Federal Ministry of Education and Research (BMBF). The company closed a series A financing round in May 2014 with a volume of € 2.7 million provided by a syndicate led by Wellington Partners. Funding was extended to a total of € 5.85 million in Oct. 2015 with an additional contribution of € 2.0 million by the lead investor. Life Science Inkubator, Kreditanstalt für Wiederaufbau (KfW) and several private shareholders also participated in the financing rounds. In addition, NEUWAY Pharma GmbH received a € 2.93 million BMBF grant in August 2015 for advancing its CNS Drug Delivery Platform.

---